Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adeona Pharmaceuticals, a specialty pharmaceutical company, has expanded its intellectual property estate through an option agreement to license with the University of Kansas relating to various uses of oral estriol for the treatment of various immunomodulatory diseases.
Subscribe to our email newsletter
B T Zhu, professor of pharmacology, toxicology and therapeutics at the University of Kansas, has demonstrated that estriol has strong immunomodulating effects versus other estrogens through its ability to reduce the risk of developing antibody-mediated immune attacks.
Trimesta (oral, once-daily estriol) is the subject of an ongoing multi-center, double-blind, placebo-controlled 150-patient Phase IIb clinical trial for the treatment of relapsing remitting multiple sclerosis (MS) which is being funded by a $5 million grant from the National Multiple Sclerosis Society in partnership with the National MS Society’s Southern California chapter, with support from the National Institutes of Health.
Nicholas Stergis, CEO of Adeona, said: “This expansion of our intellectual property through collaborative university based relationships complements our existing issued patent estate for Trimesta, which has been exclusively licensed from University of California, Los Angeles. Dr Zhu’s work may help to expand the utility of Trimesta into other autoimmune diseases.”